Latest Earnings Results: Q3 '26
Estimated EPS
-$0.19
Reported EPS
-$0.15
Surprise
+19.05%
Estimated Rev
$4.46M
Reported Rev
$10.36M
Surprise
+132.42%
• Reported GAAP EPS of -$0.15 • Reported revenue of $10.37M • Editas Medicine expects existing cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditure requirements into the second half of 2028, through and beyond key Strive study clinical readouts.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.19 | -- | -- | N/A |
Q3 '26 | -$0.19 | -$0.15 | 19.05% | BEAT |
Q2 '26 | -$0.18 | -$0.15 | 16.47% | BEAT |
Q1 '26 | -$0.26 | -$0.26 | 1.15% | BEAT |
Q4 '25 | -$0.23 | -$0.06 | 74.21% | BEAT |